content_image/1054062.jpg content_image/1054063.jpg content_image/1054067.jpg
## IMMUNOLOGY 

<img src='content_image/1054062.jpg'>

## CARDIOVASCULAR 

<img src='content_image/1054063.jpg'>

<img src='content_image/1054067.jpg'>

Note: Above pipeline excludes clinical collaborations 

## FIBROTIC DISEASES 

ª Development Partnership: OPDIVO, YERVOY , Relatlimab, EP4:  Ono (our collaboration with Ono also includes other early stage compounds); EMPLICITI :  AbbVie;  Bempegaldesleukin: Nektar; Cabiralizumab:  Five Prime Therapeutics, Inc.; Cabozantinib:  Exelixis, Inc.; ELIQUIS:  Pfizer; Factor XIa Inhibitor:  Janssen Pharmaceuticals, Inc.;  HSP47:  Nitto Denko Corporation; CD3XCD33, GEMoaB CD3xPSCA, GEM333:  GeMoaB Monoclonals GmbH; bb21217, ide-cel:  bluebird bio, Inc.; REBLOZYL :  Acceleron Pharma Inc.; IDHIFA, MAT2A:  Agios Pharmaceuticals, Inc.; AHR:  Ikena Oncology 

^ Trial(s) exploring various combinations 

# Partner-run study 

